| 2.35 Delayed Data As of Aug 22 |  -0.06 / -2.49%Today’s Change | 1.74 Today|||52-Week Range 4.40 | -8.56% Year-to-Date |
| Previous close | 2.41 |
| Today’s open | 2.43 |
| Day’s range | 2.32 - 2.54 |
| Volume | 222,657 |
| Average volume (3 months) | 411,797 |
| Market cap | $152.6M |
| Earnings growth (last year) | +5.32% |
| Earnings growth (this year) | +23.43% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +60.57% |
| P/E ratio | NM |
| Price/Sales | 17.31 |
| Price/Book | 0.71 |
| Today’s change | Today’s % change | |
|---|---|---|
| IMUXImmunic Inc | -0.22 | -1.52% |
| LXRXLexicon Pharmaceutic... | -0.05 | -3.55% |
| NBRVNabriva Therapeutics... | +0.02 | +0.98% |
| GLYCGlycoMimetics Inc | -0.12 | -3.44% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $7.2M |
| Annual profit (last year) | -$69.5M |
| Net profit margin | -962.78% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Michael A. Sherman |
Chief Financial & Business Officer Michael T. Andriole |
Corporate headquarters Durham, North Carolina |
